Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 2Lung Neoplasms 2Advanced Solid Tumors 2Thoracic Neoplasms 1Noonan Syndrome 1Non-small Cell Lung Cancer Metastatic 1Neoplasms 1Healthy Participants 1Brain Neoplasms 1Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation 1Advanced Solid Tumor 1Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation 1

Interventions

pembrolizumab 59Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 26Carboplatin 25Irinotecan 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × sotorasib × Clear all
NCT04892017 2026-04-08

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1 Terminated
91 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05480865 2024-12-12

Argonaut

Navire Pharma Inc., a BridgeBio company

Phase 1 Terminated
28 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡